Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2023)
10 slides from Immuron's shareholder meeting presentation, Nov 21, 2023
Slide 1: AGM Presentation 21 November 2023
1 1 AGM PRESENTATION 21 NOVEMBER , 2023 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO
Slide 2: Safe Harbor Statement
2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended
Slide 3: Executive Summary
3 3 EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview • Platform Technology: capable of producing highly specific ora
Slide 4: Company Highlights: Strong Sales Growth
4 4 COMPANY HIGHLIGHTS Strong Sales Growth o Global sales increased by 136% in the 2023 fiscal year to A$1.80 million compared to A$0.77 million in FY22 o Record quarterly global sales in Q1, FY24 of $1.57 million o Australia Net Sales o FY23: A$1.16 million o Q1, FY24 : A$1.35 million o 229% higher
Slide 5: Strong Pipeline with Near Term Milestones
5 5 STRONG PIPELINE WITH NEAR TERM MILESTONES 5 5 Market Phase III Phase II Phase I Partner Compound or brand name Travelan® CampETEC Market Phase III Phase II Phase I Indication Compound or brand name Traveler’s Diarrhea ETEC challenge IMM - 124E Travelan® Clostridioides difficile Infection & Recur
Slide 6: Collaborations with U.S. DoD – Remain Strong
6 6 COMPANY HIGHLIGHTS Collaborations with U.S. DoD – Remain Strong o Travelan® IND Approval – December 2022 o Study Initiation – May 2023 o First cohort recruitment completed – July 2023 o Presentations at Military Health System Research Symposium – August 2023 o Second cohort recruitment completed
Slide 7: US Naval Medical Research Command – Campylobacter & ETEC Project
7 7 COMPANY HIGHLIGHTS US Naval Medical Research Command – Campylobacter & ETEC PROJECT o New Therapeutic in Clinical Development for Treatment of moderate to severe Campylobacteriosis and Infectious diarrhea caused by ETEC pathogens o Toxicology study completed – December 2022 o FDA removed IND Cli
Slide 8: IMM-529 Clinical Development for Treatment of C. difficile Infections
8 8 COMPANY HIGHLIGHTS IMM - 529 Clinical Development for Treatment of C. difficile Infections o Opportunity Assessment Completed o C. difficile infection (CDI) affects just over ~400,000 people in the US annually o S izable number of patients who experience at least one recurrence (~20 - 25%), o M
Slide 9: Contact Information
9 9 EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Slide 10: Scientific References
10 10 SCIENTIFIC REFERENCES Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research